Clinical Trial Update: Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update assessing safety and tolerability of VK2809 in patients with primary hypercholesterolemia and non-alcoholic fatty liver disease (N…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia
• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• VK2809

Snippet

Sponsor: Viking Therapeutics, Inc. | Conditions: Hyperlipidemia, NAFLD | Phase 2 | Status: COMPLETED